FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016073054> ?p ?o ?g. }

• W2016073054 endingPage "297" @default.
• W2016073054 startingPage "290" @default.
• W2016073054 abstract "In Brief Purpose: To evaluate the immediate changes after intravitreous triamcinolone acetonide or intravitreous bevacizumab in diabetic macular edema (DME). Methods: A nonrandomized interventional study. Type 2 diabetic patients were included. Intravitreous triamcinolone acetonide (4 mg) was injected for 22 eyes with DME and IVB (1.25 mg) for 18 eyes with DME. The early time-dependent changes of central macular thickness were evaluated by optical coherence tomography before and from 1 hour to 1 month after intervention. Intravitreous bevacizumab was also tested in patients with retinal vein occlusion as a control of non-DME. Visual acuity was also examined. Results: Compared with the baseline, central macular thickness of eyes with DME decreased significantly 1 hour after intravitreous triamcinolone acetonide (P < 0.05, Wilcoxon signed rank test), while it did not significantly until 24 hours after IVB. The decrease in central macular thickness was observed significantly from 3 hours after IVB in retinal vein occlusion (P < 0.05, Wilcoxon signed rank test), and it was more evident in retinal vein occlusion than DME after IVB. Visual acuity improved significantly in DME with intravitreous triamcinolone acetonide or IVB at 1 month (P < 0.01 and P < 0.05, respectively, Wilcoxon signed rank test). Conclusion: Factors responsive to triamcinolone acetonide, other than vascular endothelial growth factor, might play an important role in pathogenesis of DME compared with retinal vein occlusion. Although no conclusion can be drawn, immediate decrease in central macular thickness after intravitreous triamcinolone acetonide might indicate the possible involvement of a nongenomic pathway of triamcinolone acetonide action. Factors responsive to triamcinolone acetonide, other than vascular endothelial growth factor, might play an important role in pathogenesis of DME compared with retinal vein occlusion. Although no conclusion can be drawn, immediate decrease in central macular thickness after intravitreous triamcinolone acetonide might indicate the possible involvement of a nongenomic pathway of triamcinolone acetonide action." @default.
• W2016073054 created "2016-06-24" @default.
• W2016073054 creator A5004278954 @default.
• W2016073054 creator A5011265483 @default.
• W2016073054 creator A5030741682 @default.
• W2016073054 creator A5072052072 @default.
• W2016073054 date "2011-02-01" @default.
• W2016073054 modified "2023-09-26" @default.
• W2016073054 title "EARLY CHANGE OF CENTRAL MACULAR THICKNESS AFTER INTRAVITREOUS TRIAMCINOLONE OR BEVACIZUMAB IN DIABETIC MACULAR EDEMA OR RETINAL VEIN OCCLUSION" @default.
• W2016073054 cites W124461014 @default.
• W2016073054 cites W127872553 @default.
• W2016073054 cites W1567760664 @default.
• W2016073054 cites W1581429301 @default.
• W2016073054 cites W1809125639 @default.
• W2016073054 cites W1969436602 @default.
• W2016073054 cites W1970259819 @default.
• W2016073054 cites W1971905187 @default.
• W2016073054 cites W1974742853 @default.
• W2016073054 cites W1976066647 @default.
• W2016073054 cites W1991727114 @default.
• W2016073054 cites W1992316134 @default.
• W2016073054 cites W1993569750 @default.
• W2016073054 cites W1996418653 @default.
• W2016073054 cites W2002152165 @default.
• W2016073054 cites W2005242911 @default.
• W2016073054 cites W2005675827 @default.
• W2016073054 cites W2007226281 @default.
• W2016073054 cites W2007263918 @default.
• W2016073054 cites W2012414883 @default.
• W2016073054 cites W2027693928 @default.
• W2016073054 cites W2043808345 @default.
• W2016073054 cites W2046813533 @default.
• W2016073054 cites W2053569960 @default.
• W2016073054 cites W2070304939 @default.
• W2016073054 cites W2074344799 @default.
• W2016073054 cites W2076725951 @default.
• W2016073054 cites W2086964414 @default.
• W2016073054 cites W2087355096 @default.
• W2016073054 cites W2087566026 @default.
• W2016073054 cites W2101319706 @default.
• W2016073054 cites W2129375983 @default.
• W2016073054 cites W2130642901 @default.
• W2016073054 cites W2141925906 @default.
• W2016073054 cites W2148230234 @default.
• W2016073054 cites W2232176731 @default.
• W2016073054 cites W3202352366 @default.
• W2016073054 doi "https://doi.org/10.1097/iae.0b013e3181eef070" @default.
• W2016073054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21102366" @default.
• W2016073054 hasPublicationYear "2011" @default.
• W2016073054 type Work @default.
• W2016073054 sameAs 2016073054 @default.
• W2016073054 citedByCount "15" @default.
• W2016073054 countsByYear W20160730542012 @default.
• W2016073054 countsByYear W20160730542013 @default.
• W2016073054 countsByYear W20160730542014 @default.
• W2016073054 countsByYear W20160730542015 @default.
• W2016073054 countsByYear W20160730542017 @default.
• W2016073054 countsByYear W20160730542019 @default.
• W2016073054 countsByYear W20160730542020 @default.
• W2016073054 crossrefType "journal-article" @default.
• W2016073054 hasAuthorship W2016073054A5004278954 @default.
• W2016073054 hasAuthorship W2016073054A5011265483 @default.
• W2016073054 hasAuthorship W2016073054A5030741682 @default.
• W2016073054 hasAuthorship W2016073054A5072052072 @default.
• W2016073054 hasConcept C118487528 @default.
• W2016073054 hasConcept C141071460 @default.
• W2016073054 hasConcept C2776251621 @default.
• W2016073054 hasConcept C2776268601 @default.
• W2016073054 hasConcept C2776694085 @default.
• W2016073054 hasConcept C2777802072 @default.
• W2016073054 hasConcept C2778257484 @default.
• W2016073054 hasConcept C2778844676 @default.
• W2016073054 hasConcept C2778903070 @default.
• W2016073054 hasConcept C2780261187 @default.
• W2016073054 hasConcept C2780347916 @default.
• W2016073054 hasConcept C71924100 @default.
• W2016073054 hasConceptScore W2016073054C118487528 @default.
• W2016073054 hasConceptScore W2016073054C141071460 @default.
• W2016073054 hasConceptScore W2016073054C2776251621 @default.
• W2016073054 hasConceptScore W2016073054C2776268601 @default.
• W2016073054 hasConceptScore W2016073054C2776694085 @default.
• W2016073054 hasConceptScore W2016073054C2777802072 @default.
• W2016073054 hasConceptScore W2016073054C2778257484 @default.
• W2016073054 hasConceptScore W2016073054C2778844676 @default.
• W2016073054 hasConceptScore W2016073054C2778903070 @default.
• W2016073054 hasConceptScore W2016073054C2780261187 @default.
• W2016073054 hasConceptScore W2016073054C2780347916 @default.
• W2016073054 hasConceptScore W2016073054C71924100 @default.
• W2016073054 hasIssue "2" @default.
• W2016073054 hasLocation W20160730541 @default.
• W2016073054 hasLocation W20160730542 @default.
• W2016073054 hasOpenAccess W2016073054 @default.
• W2016073054 hasPrimaryLocation W20160730541 @default.
• W2016073054 hasRelatedWork W2030781400 @default.
• W2016073054 hasRelatedWork W2041448642 @default.
• W2016073054 hasRelatedWork W2294668099 @default.
• W2016073054 hasRelatedWork W2368356977 @default.
• W2016073054 hasRelatedWork W2403564783 @default.

• next